Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ASHISH KAMAT and JIANJUN GAO.
ASHISH KAMAT
Connection Strength
2.068
JIANJUN GAO
  1. Long-Term Oncological Outcomes in Patients Diagnosed With Nonmetastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol. 2024 Feb; 211(2):241-255.
    View in: PubMed
    Score: 0.233
  2. Evolving systemic management of urothelial cancers. Curr Opin Oncol. 2023 05 01; 35(3):186-199.
    View in: PubMed
    Score: 0.223
  3. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.
    View in: PubMed
    Score: 0.203
  4. Reply by Authors. J Urol. 2021 11; 206(5):1267.
    View in: PubMed
    Score: 0.199
  5. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
    View in: PubMed
    Score: 0.198
  6. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu?rin. BJU Int. 2021 07; 128(1):65-71.
    View in: PubMed
    Score: 0.190
  7. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.188
  8. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urol Clin North Am. 2018 May; 45(2):155-167.
    View in: PubMed
    Score: 0.157
  9. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol. 2024 Nov; 49:100866.
    View in: PubMed
    Score: 0.062
  10. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024 Jun; 148:1-6.
    View in: PubMed
    Score: 0.060
  11. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.
    View in: PubMed
    Score: 0.058
  12. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.
    View in: PubMed
    Score: 0.053
  13. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.
    View in: PubMed
    Score: 0.053
  14. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer. 2022 04; 20(2):176-182.
    View in: PubMed
    Score: 0.051
  15. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44.
    View in: PubMed
    Score: 0.050
  16. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020 Jun 26; 23(6):101201.
    View in: PubMed
    Score: 0.046
  17. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.